StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3043% below fair value
$3.06+0.04 (+1.32%)

Close on Nov 19, 2026Market cap $246.55MP/E 13.3Yield –

Protalix BioTherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Protalix BioTherapeutics's pe ratio was 13.6× on Nov 11, 2026, against 38.8× a year earlier. Over the last 4 years it ranged from 0.9× to 155.0×, with a median of 18.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202613.6×−31.4
2025Dec 31, 202545.0×+23.4
2024Jul 31, 202421.6×−14.0
2023Dec 29, 202335.6×+34.3
2017Jan 31, 20171.3×+0.4
2016Dec 30, 20161.0×–

More Protalix BioTherapeutics figures

See a number that looks wrong?